Company intelligence / Profile preview
Adverum Biotechnologies
Redwood City, California, United Statesadverum.com ↗
- Ownership
- Public · ADVM
- Employees
- ~100
- Development stage
- Other
01
Overview
Adverum has initiated the ARTEMIS Phase 3 study in March 2025 to evaluate Ixo-vec for wet AMD. The 52-week LUNA data and 4-year OPTIC results support the long-term potential of Ixo-vec, showing maintenance of visual and anatomic endpoints with potential best-in-class injection-free rates and reduction in injection burden[7][9].
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Beyond the preview
Go deeper on Adverum Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adverum Biotechnologies.